Novo Nordisk will continue to restrict U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug most likely into 2024, it said on Thursday, as the company struggles to keep up with soaring U.S. demand. The news came as the Danish drugmaker raised its…

Read Full Article (External Site)